{Reference Type}: Journal Article
{Title}: Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia.
{Author}: Wu X;Wang F;Yang X;Gong Y;Niu T;Chu B;Qu Y;Qian Z;
{Journal}: Small
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 27
{Factor}: 15.153
{DOI}: 10.1002/smll.202403409
{Abstract}: Acute myeloid leukemia (AML) is a common and catastrophic hematological neoplasm with high mortality rates. Conventional therapies, including chemotherapy, hematopoietic stem cell transplantation (HSCT), immune therapy, and targeted agents, have unsatisfactory outcomes for AML patients due to drug toxicity, off-target effects, drug resistance, drug side effects, and AML relapse and refractoriness. These intrinsic limitations of current treatments have promoted the development and application of nanomedicine for more effective and safer leukemia therapy. In this review, the classification of nanoparticles applied in AML therapy, including liposomes, polymersomes, micelles, dendrimers, and inorganic nanoparticles, is reviewed. In addition, various strategies for enhancing therapeutic targetability in nanomedicine, including the use of conjugating ligands, biomimetic-nanotechnology, and bone marrow targeting, which indicates the potential to reverse drug resistance, are discussed. The application of nanomedicine for assisting immunotherapy is also involved. Finally, the advantages and possible challenges of nanomedicine for the transition from the preclinical phase to the clinical phase are discussed.